Company Description
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin’s lymphoma.
In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors.
In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services.
The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions.
Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
| Country | China |
| Founded | 2009 |
| IPO Date | Jan 24, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 583 |
| CEO | Dajun Yang |
Contact Details
Address: Suzhou Industrial Park, 68 Xinqing Road Suzhou, 215000 China | |
| Phone | 86 512 8555 7777 |
| Website | ascentage.cn |
Stock Details
| Ticker Symbol | AAPG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| IPO Price | $17.25 |
| CIK Code | 0002023311 |
| ISIN Number | US04390B1052 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dajun Yang, M.D., Ph.D. | Chairman, Chief Executive Officer and Director |
| Yifan Zhai, M.D., Ph.D. | Chief Medical Officer |
| Jin Cao | Head of Finance |
| Raymond Jeffrey Kmetz | Chief Business Officer |
| Thomas J. Knapp | Senior Vice President, General Counsel |
| Marina S. Bozilenko | Director |
| Simon Dazhong Lu, Ph.D. | Director |
| Wei Ren | Director |
| David Sidransky, M.D. | Director |
| Shaomeng Wang, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | 6-K | Report of foreign issuer |
| Feb 11, 2025 | 6-K | Report of foreign issuer |
| Jan 24, 2025 | 424B4 | Prospectus |
| Jan 24, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 23, 2025 | EFFECT | Notice of Effectiveness |
| Jan 23, 2025 | CERT | Certification by an exchange approving securities for listing |
| Jan 21, 2025 | 8-A12B | Registration of securities |
| Jan 21, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Dec 27, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Dec 10, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |